135 related articles for article (PubMed ID: 30167074)
1. Chk-mate on resistance to kinase inhibitors.
Shapiro P
Oncotarget; 2018 Aug; 9(60):31560-31561. PubMed ID: 30167074
[No Abstract] [Full Text] [Related]
2. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
3. Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells.
Shah T; Wildes F; Penet MF; Winnard PT; Glunde K; Artemov D; Ackerstaff E; Gimi B; Kakkad S; Raman V; Bhujwalla ZM
NMR Biomed; 2010 Jul; 23(6):633-42. PubMed ID: 20623626
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.
Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK
PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the Csk homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells.
Zagozdzon R; Bougeret C; Fu Y; Avraham HK
Int J Oncol; 2002 Dec; 21(6):1347-52. PubMed ID: 12429987
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.
Ferrao PT; Bukczynska EP; Johnstone RW; McArthur GA
Oncogene; 2012 Mar; 31(13):1661-72. PubMed ID: 21841818
[TBL] [Abstract][Full Text] [Related]
7. C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases.
Chong YP; Chan AS; Chan KC; Williamson NA; Lerner EC; Smithgall TE; Bjorge JD; Fujita DJ; Purcell AW; Scholz G; Mulhern TD; Cheng HC
J Biol Chem; 2006 Nov; 281(44):32988-99. PubMed ID: 16959780
[TBL] [Abstract][Full Text] [Related]
8. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--endogenous negative regulators of Src-family protein kinases.
Chong YP; Mulhern TD; Cheng HC
Growth Factors; 2005 Sep; 23(3):233-44. PubMed ID: 16243715
[TBL] [Abstract][Full Text] [Related]
9. Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.
Advani G; Lim YC; Catimel B; Lio DSS; Ng NLY; Chüeh AC; Tran M; Anasir MI; Verkade H; Zhu HJ; Turk BE; Smithgall TE; Ang CS; Griffin M; Cheng HC
Cell Commun Signal; 2017 Aug; 15(1):29. PubMed ID: 28784162
[TBL] [Abstract][Full Text] [Related]
10. CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Chüeh AC; Advani G; Foroutan M; Smith J; Ng N; Nandurkar H; Lio DS; Zhu HJ; Chong YP; Verkade H; Fujita DJ; Bjorge J; Basheer F; Lim JP; Luk I; Dhillon A; Sakthianandeswaren A; Mouradov D; Sieber O; Hollande F; Mariadason JM; Cheng HC
Oncogene; 2021 Apr; 40(17):3015-3029. PubMed ID: 33767439
[TBL] [Abstract][Full Text] [Related]
11. Csk homologous kinase (CHK), unlike Csk, enhances MAPK activation via Ras-mediated signaling in a Src-independent manner.
Zagozdzon R; Kaminski R; Fu Y; Fu W; Bougeret C; Avraham HK
Cell Signal; 2006 Jun; 18(6):871-81. PubMed ID: 16168623
[TBL] [Abstract][Full Text] [Related]
12. CHK Methylation Is Elevated in Colon Cancer Cells and Contributes to the Oncogenic Properties.
Zhu S; Zhu Y; Wang Q; Zhang Y; Guo X
Front Cell Dev Biol; 2021; 9():708038. PubMed ID: 34268315
[TBL] [Abstract][Full Text] [Related]
13. Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrate.
Ia KK; Jeschke GR; Deng Y; Kamaruddin MA; Williamson NA; Scanlon DB; Culvenor JG; Hossain MI; Purcell AW; Liu S; Zhu HJ; Catimel B; Turk BE; Cheng HC
Biochemistry; 2011 Aug; 50(31):6667-77. PubMed ID: 21699177
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of Csk and CHK kinases in breast cancer cells.
Bougeret C; Jiang S; Keydar I; Avraham H
J Biol Chem; 2001 Sep; 276(36):33711-20. PubMed ID: 11445575
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and biochemical characterization of Chk, a soluble protein tyrosine kinase.
Ayrapetov MK; Lee S; Sun G
Protein Expr Purif; 2003 Jun; 29(2):148-55. PubMed ID: 12767803
[TBL] [Abstract][Full Text] [Related]
16. Development of the procedures for high-yield expression and rapid purification of active recombinant Csk-homologous kinase (CHK): comparison of the catalytic activities of CHK and CSK.
Chan KC; Lio DS; Dobson RC; Jarasrassamee B; Hossain MI; Roslee AK; Ia KK; Perugini MA; Cheng HC
Protein Expr Purif; 2010 Dec; 74(2):139-47. PubMed ID: 20667476
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
Babiker HM; McBride A; Cooke LS; Mahadevan D
Expert Opin Investig Drugs; 2017 Sep; 26(9):1063-1072. PubMed ID: 28745064
[TBL] [Abstract][Full Text] [Related]
18. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
Lee BC; Lee TH; Zagozdzon R; Avraham S; Usheva A; Avraham HK
Cancer Res; 2005 Apr; 65(7):2840-5. PubMed ID: 15805285
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the Csk homologous kinase (Chk tyrosine kinase) induces multinucleation: a possible role for chromosome-associated Chk in chromosome dynamics.
Yamaguchi N; Nakayama Y; Urakami T; Suzuki S; Nakamura T; Suda T; Oku N
J Cell Sci; 2001 May; 114(Pt 9):1631-41. PubMed ID: 11309195
[TBL] [Abstract][Full Text] [Related]
20. Regulation, targets and functions of CHK.
Zhu S; Sun R; Guo X; Bao Y; Zhang D
Front Cell Dev Biol; 2022; 10():1068952. PubMed ID: 36568988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
